Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study reveals dog owner priorities for canine epilepsy research
Improving existing drug management was highlighted as a key area for future epilepsy research.
Owners rank the development of new antiepileptic medication as a high priority.

A new study has identified improving drug management as a primary area of research for owners and vets in the future treatment of canine epilepsy.

The findings, published in the Journal of Veterinary Internal Medicine, provide valuable insight into the importance of ensuring owners' views are included in future research - and that future research better improves the quality of life for affected animals and their owners. 

In the study, researchers at the RVC and the University of Veterinary Medicine Hanover undertook prioritisation activities to highlight the most important and urgent research needs. They also looked at opinions on the emerging area of non-drug therapies for epilepsy. 

A survey of 414 dog owners and specialist neurology and general practice vets revealed the areas of canine epilepsy research deemed most important. It also looked at how these views changed between 2016 and 2020.

Among the key findings were:
  • the research areas with the highest perceived importance were improving existing drug management of epilepsy, the development of new antiepileptic medication and improving the education of vets regarding epilepsy
     
  • the research areas ranked as the highest priorities were the development of new antiepileptic medication, identifying genetic causes of epilepsy, and non-drug management of epilepsy
     
  • of 10 non-drug therapies, the five rated to have the highest potential positive impact on epilepsy management were behaviour management, gene editing, CBD oil supplementation, MCT oil supplementation and epilepsy surgery
     
  • priorities differed between vets and owners, with owners prioritising day-to-day quality of life issues for their dog, such as behavioural issues or the side effects from medications. In contrast, the vet groups prioritised clinical issues, such as identifying the genetic causes of epilepsy and how different types of seizures are classified. 
Study author Dr Rowena Packer of the RVC said: “Although all of the research areas included in this prioritisation activity are important areas of investigation, ensuring that the voices of owners are heard in the planning of future research should be a broader goal in veterinary medicine, to ensure efforts are targeted at those areas most likely to improve the quality of life of both affected animals and their owners."

Co-author Professor Holger Volk of the University of Veterinary Medicine Hanover, added: "We all hope that our research makes a difference for pets, their owners and vets, but how often have we really explored what that means for the individual stakeholders? In this study, we have clearly shown that future research needs can differ depending on which group you ask. We do need to take this into account for our future research projects.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.